In partnership with Mintz, Novateur Academy and OBIO® invite venture-backed therapeutic companies to join us for a 2-day immersive masterclass on preparing for pharma business development, IP licensing strategy, deal structure, term sheets, valuation, negotiation & relationship management. These interactive sessions & case studies will be led by experienced pharma & biotech executives. The event will culminate with case-based pitches and mock licensing negotiations judged by pharma BD executives, followed by a networking reception.
Confirmed Speakers and Facilitators:
- Ali Ardakani - Chair Life Sciences BC; Associate Creative CDL; Managing Director, Novateur Ventures
- Anne Stevens - VP of BD, AbCellera; formerly Director, Aequus Pharmaceuticals
- Arpita Maiti - Head of Immunology Search & Evaluation , AbbVie; formerly Global Head Emerging Sciences, Pfizer
- Dan Zheng - Sr. Director for Oncology BD, Takeda; formerly Sr. Director Global Transactions, Sanofi
- David Kennard - Sr. Advisor BD, Novateur; formerly Corp. Development, Gilead Sciences
- David Poon - Chief Business Officer, Gandeeva Therapeutics; formerly VP of BD, Zymeworks
- Dozie Amuzie - Head, JLabs Canada
- Julia Pomoransky - Sr. Director BD, Turnstone Biologics
- Kuldeep Neote - EIR at UHN and FACIT; formerly VP External Innovations, Eli Lilly
- Lorraine Hurding - Global Diagnostics Partnering Lead for Strategy & Transactions, Roche
- Maura Campbell - CEO, OBIO; formerly VP of IP & Contracts, Turnstone Biologics
- Mike Foorer - VP of BD, AmacaThera; formerly Director Corp. Development, SteriMax
- Parimal Nathwani - CEO, Toronto Innovation Acceleration Partners
- Rebecca Ross, Director, Credit Solutions at Life Science & Healthcare SVB
- Thomas Digby - IP Advisor, Novateur Ventures; formerly Head IP, Novartis
- Yvonne Joseph - BD Partnerships, Novateur Ventures; formerly Sr. Lead BD, Daewoong Pharmaceuticals